pyrroles and an 207
pyrroles has been researched along with an 207 in 10 studies
Research
Studies (10)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 7 (70.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Groot, K; Koppan, M; Kovacs, M; Nagy, A; Schally, AV | 1 |
| Arencibia, JM; Groot, K; Halmos, G; Koppán, M; Nagy, A; Plonowski, A; Schally, AV | 1 |
| Nagy, A; Schally, AV; Szepeshazi, K | 1 |
| Nagy, A; Plonowski, A; Schally, AV | 1 |
| Arencibia, JM; Groot, K; Halmos, G; Kahán, Z; Nagy, A; Schally, AV | 1 |
| Arencibia, JM; Bajo, AM; Chatzistamou, I; Krupa, M; Nagy, A; Schally, AV | 1 |
| Nagy, A; Schally, AV | 1 |
| Halmos, G; Kanashiro, CA; Nagy, A; Schally, AV; Stangelberger, A; Szepeshazi, K | 1 |
| Halmos, G; Schally, AV; Szepeshazi, K | 1 |
| Halmos, G; Schally, AV; Seitz, S; Szepeshazi, K; Treszl, A | 1 |
Reviews
1 review(s) available for pyrroles and an 207
| Article | Year |
|---|---|
Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Endometrial Neoplasms; Epithelial Cells; Female; Gonadotropin-Releasing Hormone; Humans; Male; Ovarian Neoplasms; Prostatic Neoplasms; Pyrroles; Receptors, LHRH | 2005 |
Other Studies
9 other study(ies) available for pyrroles and an 207
| Article | Year |
|---|---|
Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone.
Topics: Animals; Antineoplastic Agents; Body Weight; Cytotoxins; Doxorubicin; Female; Gonadotropin-Releasing Hormone; Growth Hormone; Luteinizing Hormone; Menstrual Cycle; Pituitary Function Tests; Pituitary Gland, Anterior; Pyrroles; Rats; Rats, Sprague-Dawley; Thyrotropin | 1997 |
Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Doxorubicin; Drug Delivery Systems; Gonadotropin-Releasing Hormone; Humans; Male; Mice; Mice, Nude; Models, Chemical; Polymerase Chain Reaction; Prostatic Neoplasms; Pyrroles; Receptors, LHRH; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Effective treatment of advanced estrogen-independent MXT mouse mammary cancers with targeted cytotoxic LH-RH analogs.
Topics: Animals; Antineoplastic Agents; Cell Division; Doxorubicin; Drug Delivery Systems; Estrogens; Female; Gonadotropin-Releasing Hormone; Growth Inhibitors; Injections, Intravenous; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasms, Hormone-Dependent; Pyrroles | 1999 |
Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies.
Topics: Adult; Animals; Antineoplastic Agents; Bombesin; Carboxylesterase; Carboxylic Ester Hydrolases; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation, Preclinical; Drug Interactions; Drug Stability; Gonadotropin-Releasing Hormone; Half-Life; Humans; Hydrolysis; Isoflurophate; Male; Mice; Mice, Nude; Nitrophenols; Paraoxon; Pyrroles; Weight Loss | 2000 |
Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Disease Models, Animal; DNA Primers; Doxorubicin; Drug Delivery Systems; Female; Gonadotropin-Releasing Hormone; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pyrroles; Radioligand Assay; Receptors, LHRH; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Specific Pathogen-Free Organisms; Tumor Cells, Cultured | 2000 |
Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207.
Topics: Animals; Antineoplastic Agents; Doxorubicin; Drug Evaluation, Preclinical; ErbB Receptors; Female; Gonadotropin-Releasing Hormone; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Pyrroles; Receptor, ErbB-2; Receptors, LHRH; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Treatment Outcome; Tumor Cells, Cultured | 2002 |
Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
Topics: Androgens; Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Disease Progression; Doxorubicin; Gonadotropin-Releasing Hormone; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Receptors, LHRH; RNA, Messenger; Transplantation, Heterologous; Triptorelin Pamoate | 2006 |
LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Colorectal Neoplasms; Doxorubicin; Gonadotropin-Releasing Hormone; Humans; Male; Mice; Mice, Nude; Pyrroles; Receptors, LHRH; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2007 |
Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bombesin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Gonadotropin-Releasing Hormone; Humans; Immunohistochemistry; Liver Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Pyrroles; Radioligand Assay; Receptors, Bombesin; Receptors, LHRH; Receptors, Somatostatin; Transplantation, Heterologous | 2008 |